Skip to content

Safety and Tolerance Study of Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic

Study of Growth and Gastrointestinal Tolerance of an Alpha-Lactalbumin Enriched and Probiotic-Supplemented Infant Formula in Infants With Colic.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00929292
Enrollment
66
Registered
2009-06-29
Start date
2006-11-30
Completion date
2008-07-31
Last updated
2009-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colic, Growth

Keywords

Infant formula, Alpha-lactalbumin, Protein composition, Colic, Probiotics

Brief summary

The purpose of this study is to evaluate the nutritional adequacy, the digestive tolerance and the effect on colic of an alpha-lactalbumin-enriched and probiotic-supplemented infant formula.

Detailed description

This double-blind, placebo-controlled study was undertaken with 66 healthy infants with colic, aged 3 weeks to 3 months, fed a month either with the experimental formula (EF) or with the control formula (CF) and evaluated for efficacy and safety parameters at days 15 and 30. Both parents provided informed written consent.

Interventions

OTHERModilac Dahlia 1

Infant formula used for non breastfed children with colic

OTHERModilac 1

Infant formula used for non breastfed children

Sponsors

Sodilac
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
3 Weeks to 3 Months
Healthy volunteers
No

Inclusion criteria

* Healthy term infants with a gestational age ranging from 37 to 42 weeks * Non breastfed children * Infants with normal growth * Infants presenting colic defined as crying periods at least 3 hours per days, 3 days per weeks, for more than 3 weeks * These crying periods could be associated with other digestive troubles(gas, abdominal distensions, regurgitations) * Apgar score \> 5 to 7 minutes

Exclusion criteria

* Infants with severe regurgitations * Newborn currently participating in another trial * Infants presenting a metabolic, nervous or organic disease able to interfere with the study * Infants presenting lactose intolerance * Evidence of protein cow's milk allergy * Mother who wants to keep breasfeeding

Design outcomes

Primary

MeasureTime frame
Crying duration per 24 hours1 day before the first consumption ; 3 days before days 15 and 30

Secondary

MeasureTime frame
Clinical Tolerance3 days before days 15 and 30
Number of therapeutic failures (no diminution in the intensity or the frequency of the digestive symptoms)Durind the 15 first days of the diet and during the 15 last days of the diet
Number of regurgitations per day3 days before days 15 and 30
Growth ParametersDay 30
Necessary Additive treatments3 days before days 15 and 30
Parents' satisfactionDays 15 and 30
Agitation/Restlessness Period Duration3 days before days 15 and 30
Gas and abdominal distensions3 days before days 15 and 30

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026